Stockreport

Tevogen Bio Reports Series A-1 Preferred Stock Investment at $10 Conversion Price

Tevogen Bio Holdings Inc.  (TVGN) 
PDF WARREN, N.J., March 28, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings ('Tevogen Bio') (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech pioneer developi [Read more]